PreveCeutical extends private placement deadline to June 12

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) announced it has extended the closing date of its non-brokered private placement to June 12, 2026, and plans to close a second tranche by the same date.

The offering aims to raise $1,000,000 through the sale of units. Each unit consists of one common share and one-half share purchase warrant. The warrants allow holders to purchase additional shares at $0.05 each for two years from closing, subject to acceleration provisions if shares trade at $0.10 or higher for ten consecutive trading days on the Canadian Securities Exchange.

The company stated it intends to use proceeds for short loan repayments, audit and legal fees, patent costs, rodent and tissue studies, and general working capital. Finder's fees may be paid in connection with the offering.

Securities issued will be subject to a four-month and one-day statutory hold period after closing. Completion remains subject to conditions including confirmation of no objection from the CSE.

The Vancouver-based health sciences company develops preventive and curative therapies using organic and nature-identical products. Its research programs include dual gene therapy for diabetes and obesity, peptide treatments, and therapeutic products for concussion treatment.

The securities have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption.

You May Also Be Interested In

• PreveCeutical closes second tranche of private placement for $245,000
• Super League Enterprise (SLE) files for 1.07M share offering by selling stockholders
• MicroVision enters agreement to sell up to $42 million in common stock